Image Analysis Group (IAG), a global leader in clinical trial imaging and AI-enhanced biomarkers, has expanded its footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to the heart of the biotechnology and pharmaceutical sectors in the Boston area, facilitating stronger collaborations and providing localized support for clinical trials within the region.
The new Cambridge office will bolster IAG’s capabilities across various therapeutic fields such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic conditions. With this expansion, the company aims to enhance its collaboration with sponsors and contract research organizations involved in Phase I to III clinical trials and imaging-intensive development projects. Additionally, IAG plans to generate employment opportunities locally, with recruitment expected in clinical imaging operations, data science, regulatory support, and business development over the next one to two years.
IAG’s new office will underpin its comprehensive imaging services, including clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. By embedding itself in the Boston life-sciences ecosystem, IAG anticipates improved cooperation with biotechnology firms, pharmaceutical companies, academic bodies, and clinical research centers.
Operating globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region. The company collaborates with pharmaceutical, biotechnology, and medical technology companies, as well as Contract Research Organizations (CROs), on multi-center studies. Its worldwide operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, Image Analysis Group functions as an imaging Clinical Research Organization (iCRO). It aids pharmaceutical, biotechnology, and medtech companies by offering imaging-based clinical trial endpoints. IAG is active in fields such as oncology, inflammatory diseases, musculoskeletal conditions, cardiometabolic disorders, and rare diseases. Its proprietary DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial management.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.